Oppenheimer began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM) in a research note issued to investors on Monday. The firm issued a buy rating and a $6.00 price objective on the medical device company’s stock.
A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a hold rating to a buy rating and set a $2.75 price target on the stock in a report on Wednesday, December 6th. Robert W. Baird restated a hold rating and set a $3.00 price target on shares of Tandem Diabetes Care in a report on Sunday, November 19th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Tandem Diabetes Care currently has an average rating of Hold and a consensus price target of $10.54.
Tandem Diabetes Care (NASDAQ:TNDM) opened at $3.10 on Monday. The stock has a market capitalization of $127.84, a P/E ratio of -0.16 and a beta of 0.44. Tandem Diabetes Care has a twelve month low of $2.14 and a twelve month high of $25.30. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after purchasing an additional 32,991 shares during the period. Russell Investments Group Ltd. raised its position in shares of Tandem Diabetes Care by 13.5% during the third quarter. Russell Investments Group Ltd. now owns 659,993 shares of the medical device company’s stock worth $482,000 after purchasing an additional 78,748 shares during the period. Finally, Wedbush Securities Inc. raised its position in shares of Tandem Diabetes Care by 88.6% during the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after purchasing an additional 88,709 shares during the period.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.